These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8302303)

  • 21. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoamine oxidase, dopamine and Parkinson's disease.
    Oreland L
    Acta Neurol Scand Suppl; 1991; 136():60-5. PubMed ID: 1801538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.
    Kindt MV; Youngster SK; Sonsalla PK; Duvoisin RC; Heikkila RE
    Eur J Pharmacol; 1988 Feb; 146(2-3):313-8. PubMed ID: 3131149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of low oral doses of (-)-deprenyl and its metabolites on DSP-4 toxicity.
    Haberle D; Szökö E; Halász AS; Magyar K
    J Neural Transm (Vienna); 2001; 108(11):1239-47. PubMed ID: 11768624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
    Ishikawa T; Okano M; Minami A; Tsunekawa H; Satoyoshi H; Tsukamoto Y; Takahata K; Muraoka S
    Behav Brain Res; 2019 Feb; 359():353-361. PubMed ID: 30359642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
    Magyar K; Szende B; Lengyel J; Tekes K
    J Neural Transm Suppl; 1996; 48():29-43. PubMed ID: 8988460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of kaempferol as a monoamine oxidase inhibitor and potential Neuroprotectant in extracts of Ginkgo biloba leaves.
    Sloley BD; Urichuk LJ; Morley P; Durkin J; Shan JJ; Pang PK; Coutts RT
    J Pharm Pharmacol; 2000 Apr; 52(4):451-9. PubMed ID: 10813558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.
    Fozard JR; Zreika M; Robin M; Palfreyman MG
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):186-93. PubMed ID: 3937059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
    Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of long-term administration of isatin and himantan to mice on sensitivity of brain monoamine oxidase B to inhibition by deprenyl in vivo and in vitro].
    Val'dman EA; Kapitsa IG; Nerobkova LN; Aksenova LN; Buneeva OA; Medvedev AE
    Biomed Khim; 2004; 50(5):509-13. PubMed ID: 15628602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective and neuronal rescue effects of selegiline: review.
    Magyar K; Haberle D
    Neurobiology (Bp); 1999; 7(2):175-90. PubMed ID: 10591051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
    Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
    Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal selegiline: targeted effects on monoamine oxidases in the brain.
    Wecker L; James S; Copeland N; Pacheco MA
    Biol Psychiatry; 2003 Nov; 54(10):1099-104. PubMed ID: 14625153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    Knoll J
    Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoamine oxidase B inhibitor, selegiline, reduces
    Ng KP; Pascoal TA; Mathotaarachchi S; Therriault J; Kang MS; Shin M; Guiot MC; Guo Q; Harada R; Comley RA; Massarweh G; Soucy JP; Okamura N; Gauthier S; Rosa-Neto P
    Alzheimers Res Ther; 2017 Mar; 9(1):25. PubMed ID: 28359327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain.
    Fagervall I; Ross SB
    J Neurochem; 1986 Aug; 47(2):569-76. PubMed ID: 3734795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor.
    Matsumoto J; Takahashi T; Agata M; Toyofuku H; Sasada N
    Jpn J Pharmacol; 1994 May; 65(1):51-7. PubMed ID: 8089930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.